The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASH 2025 | Subsequent primary malignancies after CAR T-cell therapy for multiple myeloma
In this interview, Eli Zolotov, MD, Hackensack University Medical Center, Hackensack, NJ, presents the findings of a retrospective, multicenter observational cohort study from the US Multiple Myeloma Immunotherapy Consortium, which investigated the incidence, subtypes, and associated risk factors for subsequent primary malignancies (SPMs) in patients with multiple myeloma (MM) treated with CAR T-cell therapy in the real-world setting. This interview took place at the 67th ASH Annual Meeting and Exposition, held in Orlando, FL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
